HC Wainwright Brokers Raise Earnings Estimates for BrainsWay

BrainsWay Ltd. (NASDAQ:BWAY) – Research analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for BrainsWay in a report released on Tuesday, May 27th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.05 for the quarter, up from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay’s FY2025 earnings at $0.19 EPS.

BrainsWay Trading Down 1.2%

BWAY opened at $10.31 on Thursday. BrainsWay has a 12 month low of $5.67 and a 12 month high of $11.79. The company has a market cap of $194.57 million, a P/E ratio of 103.11 and a beta of 1.25. The business’s 50-day moving average price is $9.23 and its 200-day moving average price is $9.72.

BrainsWay (NASDAQ:BWAY) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. The firm had revenue of $11.54 million for the quarter, compared to the consensus estimate of $11.45 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BWAY. JPMorgan Chase & Co. increased its holdings in BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after purchasing an additional 11,221 shares during the period. Rhumbline Advisers increased its holdings in BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after purchasing an additional 2,144 shares during the period. ARK Investment Management LLC purchased a new position in BrainsWay during the 4th quarter valued at about $1,656,000. Sei Investments Co. purchased a new position in BrainsWay during the 4th quarter valued at about $149,000. Finally, Phoenix Financial Ltd. increased its holdings in BrainsWay by 100.8% during the 4th quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock valued at $4,552,000 after purchasing an additional 242,366 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.